FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Indonesia Stocks Face Fragile Sentiment After MSCI Warning and Market Rout 
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S. 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
